Xuebijing injection ameliorates LPS-mediated acute lung injury via multi-target synergy by alleviating inflammation and ferroptosis

Abstract

Acute lung injury (ALI) is a diffuse alveolar injury caused by infections and other predisposing factors, with associated alveolar dysfunction, pulmonary oedema, and acute respiratory failure. Currently, no specific therapeutic agents are clinically available for ALI. Xuebijing injection (XBJ) is a widely used clinical traditional Chinese medicine formulation, primarily used for respiratory infections. However, the effects and mechanisms of XBJ in ALI are not fully understood. This study demonstrated that XBJ treatment ameliorated ALI progression by heightening alveolar barrier integrity and reducing histopathological lung damage. Mechanistically, XBJ inhibited the activation of the mitogen-activated protein kinase (MAPK), nuclear factor-κB (NF-κB), and NOD-like receptor thermal protein domain associated protein 3 (NLRP3) inflammasome pathways, resulting in reduced production of key pro-inflammatory cytokines (e.g., IL-6, IL-1β, and TNF-α). It also restored immune balance by regulating Treg/Th17 cells and inhibited ferroptosis. Using integrated chemical biology approaches, pyruvate kinase M2 (PKM2), enolase 1 (ENO1), PDZ binding kinase (PBK), eukaryotic translation initiation factor 3i (EIF3I), and kelch-like ECH-associated protein 1 (Keap1) were identified as direct intracellular targets of XBJ, which was further confirmed through various chemical and biological methods. Moreover, compounds from XBJ, which is entered into the blood and lungs, such as palmitic acid, ethyl 4-hydroxy-3-methoxycinnamate, sugiol, oleic acid, and 10,12-octadecadiynoic acid, could bind to these targets, respectively. In summary, XBJ protected against lipopolysaccharide (LPS)-induced ALI by multi-targets, thereby modulasting inflammatory and immune responses, while inhibiting the MAPK/NF-κB/NLRP3 pathways and ferroptosis. These findings offered mechanistic evidence of the application value of XBJ in the treatment of ALI.

Keywords

Acute lung injury / Xuebijing injection / ALI / Multi-target synergy / Ferroptosis / MAPK/NF-κB/NLRP3

Ethical statements

All animal experiments received formal approval from the Institutional Animal Ethics Committee of Tianjin University of Traditional Chinese Medicine (Approval No. TCM-LAEC2025002s0959).

Author contributions

The authors confirm their contributions to the paper as follows: study conception and design: Qiu F, Zhang J, Sun CP; performing experiment: Hui SW, Li XY, Feng XC, Xu XR, Zhang HL, Feng ZQ, Xia Q, Jia YX; manuscript writing: Hui SW, Li XY; manuscript revision: Zhang J, Sun CP. All authors reviewed the results and approved the final version of the manuscript.

Data availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Acknowledgements

This work was supported by the Non-communicable Chronic Diseases-National Science and Technology Major Project (No. 2024ZD0528804), Support Program for Young Faculty's Research and Innovation Capability Development in Tianjin Higher Education Institutions Initiated by the Ministry of Education, Outstanding Youth Foundation of Tianjin (No. 25JCJQJC00180), Science Foundation of Tianjin (No. 25JCYBJC00620), Young Scientific and Technological Talents (Level Two) in Tianjin (No. QN20230212).

Supplementary information accompanies this paper online at: https://doi.org/10.48130/targetome-0026-0005.

References

[1] Cao LJ, Xie HT, Chu ZX, Ma Y, Wang MM, et al. 2024. Protective effect of Shenfu injection against sepsis-induced acute lung injury by suppress-ing inflammation and apoptosis through the regulation of the Janus kinase 2/signal transducer and activator of transcription 3 pathway. World Journal of Traditional Chinese Medicine 10:528-534

[2] Zhang J, Yang XT, Zhang M, Zhu QM, Yao DH, et al. 2025. Discovery of soluble epoxide hydrolase inhibitors based on the skeleton of piperine: synthesis, properties, molecular dynamics simulation, and their poten-tials in acute lung injury. Acupuncture and Herbal Medicine 5:193-204

[3] Long ME, Mallampalli RK, Horowitz JC. 2022. Pathogenesis of pneumo-nia and acute lung injury. Clinical Science 136:747-769

[4] García-Rodríguez A, Gutiérrez J, Villacorta A, Arribas Arranz J, Romero-Andrada I, et al. 2024. Polylactic acid nanoplastics (PLA-NPLs) induce adverse effects on an in vitro model of the human lung epithelium: the Calu-3 air-liquid interface (ALI) barrier. Journal of Hazardous Materials 475:134900

[5] Cai Y, Shang L, Zhou F, Zhang M, Li J, et al. 2025. Macrophage pyropto-sis and its crucial role in ALI/ARDS. Frontiers in Immunology 16:1530849

[6] Park S, Kim M, Park M, Jin Y, Lee SJ, et al. 2023. Specific upregulation of extracellular miR-6238 in particulate matter-induced acute lung injury and its immunomodulation. Journal of Hazardous Materials 445:130466

[7] Lin Y, Wang Y, Zhang Y, Lu Y, Chen J, et al. 2025. MiR-29a/b suppresses CD8⁺ T cell effector function and intestinal inflammation. Exploration 5:20240363

[8] Zhang Y, Wang X, Liu Z, Yu L. 2018. Dexmedetomidine attenuates lipopolysaccharide induced acute lung injury by targeting NLRP3 via miR-381. Journal of Biochemical and Molecular Toxicology 32:e22211

[9] Liu L, Liu Y, Zhang S, Zhang J, Meng Y, et al. 2024. Celastrol promotes apoptosis of breast cancer MDA-MB-231 cells by targeting HSDL2. Acupuncture and Herbal Medicine 4:92-101

[10] Zhong M, Wang HQ, Yan HY, Wu S, Gu ZY, et al. 2019. Santin inhibits influenza A virus replication through regulating MAPKs and NF-κB pathways. Journal of Asian Natural Products Research 21:1205-1214

[11] Huang QF, Zeng JM, Hu YL, Li WY, Yu QH, et al. 2025. Lifei Qingchang Tang attenuates acute lung injury via the NF-κB and MAPK signaling pathways. Journal of Asian Natural Products Research 27:1690-1705

[12] Zhang J, Yan J, Dong H, Zhang R, Chang J, et al. 2025. Dimeric sesquiterpenoids with anti-inflammatory activities from Inula britan-nica. Chinese Journal of Natural Medicines 23:961-971

[13] Tang X, Sun L, Wang G, Chen B, Luo F. 2018. RUNX1: a regulator of NF-κB signaling in pulmonary diseases. Current Protein & Peptide Science 19:172-178

[14] Sun CP, Zhou JJ, Yu ZL, Huo XK, Zhang J, et al. 2022. Kurarinone allevi-ated Parkinson's disease via stabilization of epoxyeicosatrienoic acids in animal model. Proceedings of the National Academy of Sciences of the United States of America 119:1-9

[15] de Castro LR, de Oliveira LD, Milan TM, Eskenazi APE, Bighetti-Trevisan RL, et al. 2024. Up-regulation of TNF-alpha/NFkB/SIRT 1 axis drives aggressiveness and cancer stem cells accumulation in chemoresistant oral squamous cell carcinoma. Journal of Cellular Physiology 239:e31164

[16] Jiang L, Zhang L, Kang K, Fei D, Gong R, et al. 2016. Resveratrol amelio-rates LPS-induced acute lung injury via NLRP 3 inflammasome modula-tion. Biomedicine & Pharmacotherapy 84:130-138

[17] Bauernfeind FG, Horvath G, Stutz A, Alnemri ES, MacDonald K, et al. 2009. Cutting edge: NF-κB activating pattern recognition and cytokine receptors license NLRP 3 inflammasome activation by regulating NLRP3 expression. The Journal of Immunology 183:787-791

[18] García-Fernández A, Sancho M, Garrido E, Bisbal V, Sancenón F, et al. 2023. Targeted delivery of the pan-inflammasome inhibitor MM01 as an alternative approach to acute lung injury therapy. Advanced Health-care Materials 12:e2301577

[19] Xu Z, Li J, Zhou K, Wang K, Hu H, et al. 2024. Exocarpium Citri Grandis ameliorates LPS-induced acute lung injury by suppressing inflamma-tion, NLRP 3 inflammasome, and ferroptosis. Journal of Ethnopharma-cology 329:118162

[20] Zhao Z, Li H, Wang X, Wan Q, Wang J, et al. 2025. Therapeutic materials for ferroptosis inhibition: from design to applications. Advanced Health-care Materials Early view:e03407

[21] Johnson ER, Matthay MA. 2010. Acute lung injury: epidemiology, pathogenesis, and treatment. Journal of Aerosol Medicine and Pulmonary Drug Delivery 23:243-252

[22] Fang X, Cai Z, Wang H, Han D, Cheng Q, et al. 2020. Loss of cardiac ferritin H facilitates cardiomyopathy via Slc7a11-mediated ferroptosis. Circulation Research 127:486-501

[23] Chen X, Kang R, Kroemer G, Tang D. 2021. Ferroptosis in infection, inflammation, and immunity. The Journal of Experimental Medicine 218:e20210518

[24] Gammella E, Recalcati S, Rybinska I, Buratti P, Cairo G. 2015. Iron-induced damage in cardiomyopathy: oxidative-dependent and independent mechanisms. Oxidative Medicine and Cellular Longevity 2015:230182

[25] Zhang M, Zheng R, Liu WJ, Hou JL, Yang YL, et al. 2023. Xuebijing injec-tion, a Chinese patent medicine, against severe pneumonia: current research progress and future perspectives. Journal of Integrative Medicine 21:413-422

[26] Song Y, Yao C, Yao Y, Han H, Zhao X, et al. 2019. XueBiJing injection versus placebo for critically Ill patients with severe community-acquired pneumonia: a randomized controlled trial. Critical Care Medicine 47:e735-e743

[27] Xing Y, Hua YR, Shang J, Ge WH, Liao J. 2020. Traditional Chinese medicine network pharmacology study on exploring the mechanism of Xuebijing Injection in the treatment of coronavirus disease 2019. Chinese Journal of Natural Medicines 18:941-951

[28] He F, Wang J, Liu Y, Wang X, Cai N, et al. 2018. Xuebijing injection induces anti-inflammatory-like effects and downregulates the expres-sion of TLR4 and NF-κB in lung injury caused by dichlorvos poisoning. Biomedicine & Pharmacotherapy 106:1404-1411

[29] Xie S, Yan P, Yao C, Yan X, Huo Y, et al. 2019. Efficacy and safety of Xuebijing injection and its influence on immunomodulation in acute exacerbations of chronic obstructive pulmonary disease: study proto-col for a randomized controlled trial. Trials 20:136

[30] Wang L, Liu Z, Dong Z, Pan J, Ma X. 2016. Effects of Xuebijing injection on microcirculation in septic shock. Journal of Surgical Research 202:147-154

[31] Zou F, Zou J, Du Q, Liu L, Li D, et al. 2025. XueBiJing injection improves the symptoms of sepsis-induced acute lung injury by mitigating oxida-tive stress and ferroptosis. Journal of Ethnopharmacology 337:118732

[32] Zhang J, Zhang M, Huo XK, Ning J, Yu ZL, et al. 2023. Macrophage inac-tivation by small molecule wedelolactone via targeting sEH for the treatment of LPS-induced acute lung injury. ACS Central Science 9:440-456

[33] Fan E, Brodie D, Slutsky AS. 2018. Acute respiratory distress syndrome: advances in diagnosis and treatment. JAMA 319:698-710

[34] Hewitt RJ, Lloyd CM. 2021. Regulation of immune responses by the airway epithelial cell landscape. Nature Reviews Immunology 21:347-362

[35] Chumbley LB, Boudreaux CE, Coats KS. 2013. Aberrant placental immune parameters in the feline immunodeficiency virus (FIV)-infected cat suggest virus-induced changes in T cell function. Virology Journal 10:238

[36] Feng YL, Xu XR, Zhu QM, Chang J, Zhang HL, et al. 2024. Aucklandiae radix targeted PKM2 to alleviate ulcerative colitis: insights from the photocrosslinking target fishing technique. Phytomedicine 134:155973

[37] Cheng Y, Zhu L, Xie S, Lu B, Du X, et al. 2024. Relationship between ferroptosis and mitophagy in acute lung injury: a mini-review. PeerJ 12:e18062

[38] Liu P, Feng Y, Li H, Chen X, Wang G, et al. 2020. Ferrostatin-1 alleviates lipopolysaccharide-induced acute lung injury via inhibiting ferroptosis. Cellular & Molecular Biology Letters 25:10

[39] Zhang J, Luan ZL, Huo XK, Zhang M, Morisseau C, et al. 2023. Direct targeting of sEH with alisol B alleviated the apoptosis, inflammation, and oxidative stress in cisplatin-induced acute kidney injury. Interna-tional Journal of Biological Sciences 19:294-310

[40] Li JJ, Yao Q, Dong M, Wang Y, Xiu Y, et al. 2025. Digitoflavone amelio-rates acute lung injury via disturbing the formation of functional stimu-lator of interferon genes signalosome. World Journal of Traditional Chinese Medicine 11:182-194

[41] Li Y, Huang L, Li J, Li S, Lv J, et al. 2024. Targeting TLR4 and regulating the Keap1/Nrf2 pathway with andrographolide to suppress inflamma-tion and ferroptosis in LPS-induced acute lung injury. Chinese Journal of Natural Medicines 22:914-928

[42] Su D, Jiao Z, Li S, Yue L, Li C, et al. 2023. Spatiotemporal single-cell tran-scriptomic profiling reveals inflammatory cell states in a mouse model of diffuse alveolar damage. Exploration 3:20220171

[43] Hu Y, Xu Y, Gao J, Ling B, Pan S, et al. 2025. Integrated metabolomics and network pharmacology reveal the mechanisms of Xuebijing in counteracting sepsis-induced myocardial dysfunction. Journal of Ethnopharmacology 347:119729

[44] Cao JP, Piao XH, Zhu LX, Feng PF. 2024. Xuebijing and somatostatin against acute pancreatitis: a systematic review and network pharma-cology. Medicine 103:e40964

[45] Ling B, Ji J, Huang Q, Xu Y, Hu Y, et al. 2025. Xuebijing injection allevi-ates sepsis-induced acute lung injury by inhibition of cell apoptosis and inflammation through the hippo pathway. Journal of Inflammation Research 18:7717-7733

[46] Liu YL, Liu YJ, Liu Y, Li XS, Liu SH, et al. 2014. Hydroxysafflor yellow A ameliorates lipopolysaccharide-induced acute lung injury in mice via modulating toll-like receptor 4 signaling pathways. International Immunopharmacology 23:649-657

[47] Deng S, Li J, Li L, Lin S, Yang Y, et al. 2023. Quercetin alleviates lipopolysaccharide-induced acute lung injury by inhibiting ferroptosis via the Sirt1/Nrf2/Gpx 4 pathway. Journal of Molecular Medicine 52:118

[48] Chen R, Duffy Á, Petrazzini BO, Vy HM, Stein D, et al. 2024. Expanding drug targets for 112 chronic diseases using a machine learning-assisted genetic priority score. Nature Communications 15:8891

[49] Zhang J, Zhang M, Zhu QM, Xu XR, Feng YL, et al. 2024. Allosteric regu-lation of Keap1 by 8β-hydroxy-α-cyclocostunolide for the treatment of acute lung injury. Acta Pharmaceutica Sinica B 14:4174-4178

[50] Wang H, Gao H, Zhang Z, Zhang X, Chen X, et al. 2025. COMET: a machine-learning framework integrating ligand-based and target-based algorithms for elucidating drug targets. Journal of Medicinal Chemistry 68:26466-26477

[51] Liu P, Huang F, Zheng X, Hao H. 2025. Targetome-guided combination drug discovery as next-generation therapeutics. Targetome 1:e002

[52] Hao H, Kirchhoff F. 2025. Navigating drug discovery with Targetome. Targetome 1:e001

[53] Narita S, Kobayashi N, Mori K, Sakurai K. 2019. Clickable gold nanoparti-cles for streamlining capture, enrichment and release of alkyne-labelled proteins. Bioorganic & Medicinal Chemistry Letters 29:126768

[54] Wu M, Jia G, Liu Y, Lou Y, Li Y, et al. 2025. PKM2 controls cochlear development through lactate-dependent transcriptional regulation. Proceedings of the National Academy of Sciences of the United States of America 122:e2410829122

[55] Wang Y, Liu J, Jin X, Zhang D, Li D, et al. 2017. O-GlcNAcylation destabi-lizes the active tetrameric PKM2 to promote the Warburg effect. Proceedings of the National Academy of Sciences of the United States of America 114:13732-13737

[56] Qiao G, Wu A, Chen X, Tian Y, Lin X. 2021. Enolase 1, a moonlighting protein, as a potential target for cancer treatment. International Jour-nal of Biological Sciences 17:3981-3992

[57] Chen LJ, Li JY, Nguyen P, He M, Chen ZB, et al. 2024. Single-cell RNA sequencing unveils unique transcriptomic signatures of endothelial cells and role of ENO1 in response to disturbed flow. Proceedings of the National Academy of Sciences of the United States of America 121:e2318904121

[58] Huang H, Lee MH, Liu K, Dong Z, Ryoo Z, et al. 2021. PBK/TOPK: an effective drug target with diverse therapeutic potential. Cancers 13:2232

[59] Zhang J, Zhang HL, Xu XR, Feng YL, Zhu QM, et al. 2025. Targeting PBK with small-molecule 1-O-acetyl-4R, 6S-britannilactone for the treat-ment of neuroinflammation. Proceedings of the National Academy of Sciences of the United States of America 122:e2502593122

[60] Ma S, Dong Z, Cui Q, Liu JY, Zhang JT. 2021. eIF3i regulation of protein synthesis, cell proliferation, cell cycle progression, and tumorigenesis. Cancer Letters 500:11-20

[61] Kuai L, Xiang YW, Chen QL, Ru Y, Yin SY, et al. 2022. PD-L 1 triggered by binding eIF3I contributes to the amelioration of diabetes-associated wound healing defects by regulating IRS4. Journal of Investigative Dermatology 142:220-231.e8

[62] Geertsema S, Bourgonje AR, Fagundes RR, Gacesa R, Weersma RK, et al. 2023. The NRF2/Keap1 pathway as a therapeutic target in inflamma-tory bowel disease. Trends in Molecular Medicine 29:830-842

[63] Awuh JA, Haug M, Mildenberger J, Marstad A, Do CPN, et al. 2015. Keap1 regulates inflammatory signaling in Mycobacterium avium-infected human macrophages. Proceedings of the National Academy of Sciences of the United States of America 112:E4272-E4280

[64] Tunc R, Ates I, Yılmaz B, Medoro A, Davinelli S, et al. 2025. Modulating Nrf 2 to control lipid peroxidation and ferroptosis: implications for cancer management. Frontiers in Oncology 15:1701249